

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Mark A. Dombroski, et al.

Examiner:

Evelyn Mei Huang

Serial No:

10/649,255

Art Unit:

1625

Filed:

August 27, 2003

Docket:

17569 (PC23304A)

For:

CYCLOALKYL-

Dated:

July 11, 2005

[4-(DIFLUOROPHENYL) -OXAZOL-5-YL]-TRIAZOLO-

**PYRIDINES** 

Confirmation No.: 5909

Mail Stop Duplicates Commissioner for Patents P. O. Box 1450

Alexandria, VA 22313-1450

# **RESPONSE TO NOTICE UNDER 37 C.F.R. §1.251-PENDING APPLICATION**

Sir:

Applicants herein make available to the United States Patent and Trademark Office a copy of the PTO-FB-A820 form, which was previously filed on August 27, 2003, for the above-referenced patent application. Also enclosed are copies of the references (except U.S. Patent documents) cited by the Applicants in PTO-FB-A820 form.

# **CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Duplicates, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: July 11, 2005

Applicants submit that the enclosed Information Disclosure Statement filed August 27, 2003 and associated references is a complete and accurate copy of applicant's record of such papers.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Applicants submit the following response for entry in the above-identified case.

Respectfully submitted,

Peter I. Bernstein

Registration No. 43,497

Scully, Scott, Murphy & Presser 400 Garden City Plaza, Suite 300 Garden City, New York 11530 (516) 742-4343

PIB/RLB:dg

JUL 1 3 2005

Approved for use through 07/31/2006,OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DOMBROSKI, MARK A. et al

Application No.:

10/649255

Filing Date:

08/27/03

OPHENYL)-OXAZOL-5-YL) Title: CYCLOALKY

Direct to:

U. S. Patent and Trademark Office Mail Stop: Duplicates Commissioner for Patents P.O. Box 1450

Alexandria, Virginia 22313-1450

# NOTICE UNDER 37-CFR-1-251 — Pending Application

#### Statement (check the appropriate box):

The copy submitted with this reply is a complete and accurate copy of applicant's record of all of the correspondence between the Office and the applicant for the above-identified application (except for U.S. patent documents); and applicant is not aware of any correspondence between the Office and applicant for the above-identified application that is not among applicant's records.

The copy of the paper(s) listed in the notice under 37 CFR 1.251 is/are a complete and accurate copy of applicant's record of such paper(s).

The papers produced by applicant are applicant's complete record of all of the correspondence between the Office and the applicant for the above-identified application (except for U.S. patent documents), and applicant is not aware of any correspondence between the Office and the applicant for the above-identified application that is not among applicant's records.

Applicant does not possess any record of the correspondence between the Office and the applicant for the above identified application.

Peter I. Bernstein

Typed or printed name

### A Copy of this notice should be returned with the reply.

Burden Hour Statement: This collection of information is required by 37 CFR 1.251. The information is used by the public to reply to a request for copies of correspondence between the applicant and the USPTO in order to reconstruct an application file. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 60 minutes to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

PTO Doc Code: R251.RES (Rev. 03/05)

Patent Application Attorney Docket No.: PC23304A

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: DOMBROSKI, ET AL. :

APPLICATION NO.: NOT YET ASSIGNED

: Examiner: NOT ASSIGNED

FILING DATE:

HEREWITH

: Group Art Unit: NOT ASSIGNED

TITLE:

CYCLOALKYL-14-

(DIFLUOROPHENYL)-OXAZOL-5-

YL]-TRIAZOLO-PYRIDINES

Mail Stop PATENT APPLICATION

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

### INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicants herein make available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicants, copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Attorney for Applicants 36.99 Reg. No.

Pfizer Inc

Patent Department, 5th Floor 150 East 42nd Street

New York, NY 10017-5755

(212) 573-1229

USERS\DOCS\LA21952\LPGXB\HP\\B011.DOC / 209747 INFORMATION DISCLOSURE STATEMENT, 05/03, (1/1)

Express Mail No. EL 639816799 US

INFORMATION DESCLOSURE CAPATION
(Use several sheets # Recessary) SERIAL NO. **NOT ASSIGNED** ATTY. DOCKET NO. PC23304A APPLICANT DOMBROSKI, ET AL. **NOT ASSIGNED GROUP** FILING DATE HEREWITH **U.S. PATENT DOCUMENTS** SUBCLASS FILING DATE NAME CLASS EXAMINER INITIAL DOCUMENT NUMBER APPROPRIATE 235.8 2/10/98 ADAMS, ET AL 514 5 9 5 5 7 6 9 2 2/10/98 ADAMS, ET AL. 514 341 194 0 0 2/10/98 SELNICK, ET AL. 546 5/26/98 ADAMS, ET AL. 514 235.8 5 7 5 6 9 9 4 0 7/7/98 LEE, ET AL. 536 24.31 5 9/11/01 ADAMS, ET AL. 236.8 2 n 514 8 8 **FOREIGN PATENT DOCUMENTS** CLASS SUBCLASS COUNTRY DOCUMENT NUMBER DATE YES NO 1/14/99 PCT C07D 401/04 9 9 0 403/14 12/2/99 PCT C07D 9 0 9 6 1 4 4 2/10/00 PCT C07D 401/04 0 0 0 6 5 6 3 0 0 3 0 6 5 6/2/00 PCT C07D 401/04 405/14 0 0 9 6/22/00 **PCT** C07D 3 5 1 1 **PCT** 31/444 0 0 0 2 7/13/00 A61K 0 0 6 9 8 7/20/00 PCT A61K 31/535 413/00 0 2 0 10/26/00 PCT C07D 3 PCT C07D 403/14 7 9/19/02 n 2 2 5 6 0 2 7 9 9/19/02 PCT C07D 471/04 10/9/02 EΡ C07D 403/04 8 0 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) The Journal of Biological Chemistry, Vol. 271, No. 40, pp. 24313-24316 (1996); Bioorganic & Medicinal Chemistry Letters, 10, pp. 2047-2050 (2000); and Bioorganic & Medicinal Chemistry Letters, 11, pp. 9-12 (2001). **EXAMINER** DATE CONSIDERED EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to apolicant.

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE